Scottish tech company Novosound has developed an ultrasonic blood pressure monitor, claimed to be the first in the world, designed to miniaturise and enhance the accuracy of blood pressure monitoring in wearable devices.
This innovation promises to bring medical-grade monitoring to everyday wearables such as smartwatches and rings.
Go deeper with GlobalData
Built on the company’s Slanj platform, this technology is not just a laboratory concept but has been tested in real-world environments.
Novosound’s collaboration at the Texas Medical Centre earlier laid the groundwork for this advancement, which now stands to transform the way blood pressure is monitored through wearable technology.
The credibility of the system was showcased at the IEEE International Ultrasonics Symposium in Taipei last month, where they presented data demonstrating accuracy on par with traditional cuff devices.
Novosound founder and CEO Dave Hughes said: “Scotland has long been at the forefront of ultrasound innovation, and we are proud to continue this legacy. Monitoring blood pressure with ultrasound, and without the need for a cuff, marks a significant advancement in how we can address global health and wellness issues.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe Slanj platform’s capabilities extend beyond blood pressure monitoring, with potential applications in hydration tracking, muscle health, and gesture control.
The company’s recent funding success, securing $2.6m led by Par Equity and contributions from Kelvin Capital, the University of the West of Scotland, and Scottish Enterprise, will expedite the commercial rollout of its ultrasound solution.
Par Equity managing partner Paul Munn said: “With innovation at its core, we are pleased to continue our support for Dave and the team as the company accelerates internationalisation and global sales. We can see the traction the company is gaining with some of the world’s largest corporate brands, with considerable commercial opportunities ahead in digital health and industrial monitoring markets.”
Novosound is set to exhibit these advanced technologies at CES 2025 in Las Vegas in January, further establishing its presence in the wearable tech market.
